Furthermore, it has been proposed that the baseline immune profile and the analysis of the tumor growth dynamics on treatment can guide optimal selection and identify the rapid tumor growth induced by PD-1 inhibitors in HCC patients earlier (104). Here, PDCD1 is linked to hepatocellular carcinoma.